26 completed, 19 unknown, 8 terminated, 6 recruiting. 64 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 64 | Completed 26, Unknown 19, Terminated 8, Recruiting 6, Withdrawn 4, Not yet recruiting 1 |
Follow Blood Platelet Disorders: new trials by email Literature Review of Blood Platelet Disorders trials Research Report on Blood Platelet Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia standard-dose methylprednisolone/prednisone., thrombopoietin receptor agonist(TPO-RA), including but not limited to hetrombopag or eltrombopag., rituximab. - ITP - Immune Thrombocytopenia | Phase 4 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 38 | 2026-06-22 | 2026-08-26 |
| Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS Ravulizumab - aHUS, Atypical Hemolytic Uremic Syndrome | Phase 4 | Recruiting | Alexion Pharmaceuticals, Inc. | 20 | 2025-12-19 | 2026-04-20 |
| Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP Eltrombopag, Placebo - Primary Immune Thrombocytopenia (ITP) | Phase 4 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 150 | 2025-12-01 | 2025-09-24 |
| Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study Avatrombopag 20 mg Oral Tablet - ITP - Immune Thrombocytopenia | Phase 4 | Recruiting | Al-Mustansiriyah University | 25 | 2025-06-08 | 2025-08-21 |
| Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia Sirolimus, Placebo - Antiphospholipid (aPL)-Positive, Thrombocytopaenia | Phase 4 | Recruiting | Peking University First Hospital | 84 | 2025-01-07 | 2026-06-30 |
| Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of Thrombocytopenia Hetrombopag - Thrombocytopenia | Phase 4 | Unknown | The Third People's Hospital of Chengdu | 55 | 2024-06-01 | 2024-08-20 |
| Efficacy of Intravenous N-Acetylcysteine in Preventing Linezolid-Induced Thrombocytopenia in Critically Ill Patients N acetyl cysteine, Placebo - Linezolid, Antioxidant | Phase 4 | Completed | Helwan University | 250 | 2023-08-01 | 2025-07-14 |
| TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) TPO-RAs, TPO-RAs combining anti-CD 20 monoclonal antibody - Primary Immune Thrombocytopenia (ITP) | Phase 4 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 166 | 2023-02-23 | 2024-07-30 |
| A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts rhTPO, Eltrombopag - Previously Treated Primary Immune Thrombocytopenia | Phase 4 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 157 | 2022-11-22 | 2025-04-24 |
| Short-course High-dose Prednisone and Dexamethasone in Children With ITP Prednisone, Dexamethasone - Immune Thrombocytopenia, Glucocorticoids | Phase 4 | Unknown | Fujian Medical University Union Hospital | 608 | 2022-10-11 | 2024-05-16 |
| STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis Enoxaparin, Dalteparin, Tinzaparin - Cancer-associated Thrombosis, Thrombocytopenia | Phase 4 | Recruiting | Tzu-Fei Wang | 50 | 2022-08-29 | 2025-12-17 |
| Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients 2.5mg/d Hetrombopag - Primary Immune Thrombocytopenia | Phase 4 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 69 | 2022-05-01 | 2022-04-05 |
| Efficacy and Safety of Avatrombopag for Treating TCP in HBV-ACLF Patients Receiving ALSS Treatment Avatrombopag, Artificial Liver Support System, Comprehensive internal medical treatment. - Thrombocytopenia, Hepatitis B, Chronic | Phase 4 | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 60 | 2022-04-27 | 2022-11-10 |
| Effects of Recombinant Human Thrombopoietin on Platelet Levels in ICU Patients recombinant human thrombopoietin, normal saline - Pneumonia, Thrombocytopenia | Phase 4 | Unknown | Nanfang Hospital, Southern Medical University | 178 | 2022-02-01 | 2022-02-01 |
| Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP Bortezomib Injection - Thrombotic Thrombocytopenic Purpura, Acquired | Phase 4 | Unknown | Peking Union Medical College Hospital | 30 | 2021-12-01 | 2021-11-26 |
| Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure Avatrombopag maleate, Platelet transfusion, Medicine - Thrombocytopenia; Drugs, Chronic Liver Disease | Phase 4 | Unknown | Chinese PLA General Hospital | 476 | 2021-06-06 | 2022-11-15 |
| Avatrombopaq In Patients With Cirrhosis Doptelet Pill - Thrombocytopenia; Drugs, Cirrhosis, Liver | Phase 4 | Unknown | Hvidovre University Hospital | 20 | 2021-06-01 | 2021-04-15 |
| NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients. Pharmacokinetics, Dosage of Niraparib - Adult Patients With Platinum-sensitive, Relapsed, High Grade Serous Epithelial Ovarian Cancer | Phase 4 | Terminated | Hospices Civils de Lyon | 12 | 2021-05-05 | 2025-05-22 |
| Rifaximin in Cirrhosis: Effects on Endotoxin and Haemostatic Indexes Rifaximin, Placebo - Liver Cirrhosis, Coagulation Disorder | Phase 4 | Terminated | University of Roma La Sapienza | 20 | 2021-04-03 | 2024-10-08 |
| Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim Avatrombopag Oral Tablet - Immune Thrombocytopenia | Phase 4 | Completed | Sobi, Inc. | 60 | 2021-03-15 | 2025-01-16 |
Showing 20 of 64. Sign in to see all of them.
Purpura, Thrombocytopenic, Idiopathic (26) · Thrombocytopenia (26) · von Willebrand Diseases (4) · Liver Cirrhosis (3) · Thrombocythemia, Essential (3) · Atypical Hemolytic Uremic Syndrome (2) · Blood Coagulation Disorders (2) · Hematologic Diseases (2) · Hemophilia A (2) · Hemostatic Disorders (2) · Hepatitis C (2) · Kaposiform Hemangioendothelioma (2) · Kasabach-Merritt Syndrome (2) · Purpura (2)
Hemic and Lymphatic Diseases (64) · Hematologic Diseases (62) · Cytopenia (55) · Pathologic Processes (36) · Pathological Conditions, Signs and Symptoms (36) · Blood Coagulation Disorders (34) · Hemorrhagic Disorders (33) · Thrombotic Microangiopathies (32) · Hemorrhage (29) · Signs and Symptoms (29) · Skin Manifestations (29) · Thrombocytopenia (29) · Immune System Diseases (28) · Purpura, Thrombocytopenic (28)
eltrombopag (10) · Dexamethasone (7) · avatrombopag (6) · Sirolimus (4) · Thrombopoietin (4) · Prednisone (3) · Rituximab (3) · romiplostim (3) · Azathioprine (2) · Methylprednisolone (2) · Rifaximin (2) · argatroban (2) · hetrombopag (2) · Acetylcysteine (1) · Adrenal Cortex Hormones (1)
Shandong University (6) · Institute of Hematology & Blood Diseases Hospital, China (5) · Assiut University (3) · CSL Behring (3) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (3) · Children's Hospital of Fudan University (2) · GlaxoSmithKline (2) · Novartis Pharmaceuticals (2) · Peking Union Medical College Hospital (2) · Al-Mustansiriyah University (1) · Alexion Pharmaceuticals, Inc. (1) · Amgen (1) · Chinese PLA General Hospital (1) · Encysive Pharmaceuticals (1) · Fayoum University Hospital (1)
China (26) · United States (7) · Egypt (5) · France (5) · Italy (4) · Germany (3) · Poland (3) · South Korea (3) · Austria (2) · Bulgaria (2) · Greece (2) · Hong Kong (2) · Hungary (2) · Romania (2) · Serbia (2)
Kai Li, MD, PhD (2) · Ming Hou, MD, PhD (2) · Ahmed A. Gomaa, MD (1) · Alejandro Balestracci, MD, PhD (1) · Anne S von Krogh, MD (1) · Chanyuan WU, MD (1) · Dietmar Fries, Univ-Prof.Dr (1) · Heng Mei (1) · Heng Mei, PhD (1) · Hu Yu, M.D., Ph.D (1) · Ingrid Pabinger, Prof. Dr. (1)
PMID 19005182, PMID 15661401, PMID 19446149, PMID 20178723, PMID 20546023, PMID 20739054, PMID 21674758, PMID 21710166, PMID 22054810, PMID 22338149, PMID 22409309, PMID 2279341, PMID 23293082, PMID 23389750, PMID 23556122, PMID 24254965, PMID 25296772, PMID 25344113, PMID 25543701, PMID 26231455, PMID 26480931, PMID 26688484, PMID 27040278, PMID 27734464, PMID 29042367, PMID 29426286, PMID 30368038, PMID 31753773, PMID 31770441, PMID 31794604, PMID 33115308, PMID 33123978, PMID 33200217, PMID 33270832, PMID 33314078, PMID 34528239, PMID 34587675, PMID 34605871, PMID 34962697, PMID 35049070, PMID 35166922, PMID 37735543, PMID 37765023, PMID 39301879, PMID 40101243, PMID 40846660, PMID 40896456, PMID 41577060, PMID 8217798
2004 (1)